Details

Autor(en) / Beteiligte

• Tamari, R
• Mughal, T I
• Rondelli, D
• Hasserjian, R
• Gupta, V
• Odenike, O
• Fauble, V
• Finazzi, G
• Pane, F
• Mascarenhas, J
• Prchal, J
• Giralt, S
• Hoffman, R

Titel

Allo-SCT for myelofibrosis: reversing the chronic phase in the JAK inhibitor era?

Ist Teil von

• Bone marrow transplantation (Basingstoke), 2015-05, Vol.50 (5), p.628-636

Ort / Verlag

London: Nature Publishing Group UK

Erscheinungsjahr

2015

Quelle

MEDLINE

Beschreibungen/Notizen

• At present, allo-SCT is the only curative treatment for patients with myelofibrosis (MF). Unfortunately, a significant proportion of candidate patients are considered transplant ineligible due to their poor general condition and advanced age at the time of diagnosis. The approval of the first JAK inhibitor, ruxolitinib, for patients with advanced MF in 2011 has had a qualified impact on the treatment algorithm. The drug affords substantial improvement in MF-associated symptoms and splenomegaly but no major effect on the natural history. There has, therefore, been considerable support for assessing the drug’s candidacy in the peritransplant period. The drug’s precise impact on clinical outcome following allo-SCT is currently not known; nor are the drug’s long-term efficacy and safety known. Considering the rarity of MF and the small proportion of patients who undergo allo-SCT, well designed collaborative efforts are required. In order to address some of the principal challenges, an expert panel of laboratory and clinical experts in this field was established, and an independent workshop held during the 54th American Society of Hematology Annual Meeting in New Orleans, USA on 6 December 2013, and the European Hematology Association's Annual Meeting in Milan, Italy on 13 June 2014. This document summarizes the results of these efforts.